u/nadia_bakker

cite the paper: journal, year, first author, links optional

This is the "correlation is mechanism" thing again. You changed three variables at once.

Not to be pedantic but incretin and gastric emptying are being used interchangeably and they are not interchangeable in real life.

EU rules is usually a national question wearing a hat

Adding to this: Apotheke is doing more work than the comment implies.

Yeah, glucagon co-agonism is genuinely different.

gastric emptying is real and explains most early nausea

This is the "correlation is mechanism" thing again. You changed three variables at once.

the safety profile is not just tirzepatide amplified

This is correct. The co-agonism is real.

This is correct. Rodent data is investigational, not predictive.

rodent pharmacology tells you what to investigate, not what to expect in humans

EMA notices are different from national ones

my ALT moved before the scale did and i nearly missed it

Yeah, glucagon co-agonism is genuinely different.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

This is the "correlation is mechanism" thing again. You changed three variables at once.

not approved anywhere, keep posts descriptive, not instructional

Disagree but this is the good kind of wrong — it is specific enough to be checked.

The satiety on amylin analogs is described as physically different. GLP-1 reduces appetite noise, amylin does amylin.

This is correct. Rodent data is investigational, not predictive.